James Rudick, MD
Endocrinology, Diabetes & Metabolism · Canton, OHNPI 1417062928
Payments from drug & device makers
Across 103 payments — averaging $17.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$325
- Lilly USA, LLC$220
- AstraZeneca$164
- Medtronic$151
- Amryt Pharma Holdings Ltd$106
- Corcept Therapeutics$98
- plus $715 from 19 others
What the payments were for
- Food & beverage$1,75699%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 18 | $325 |
| Lilly USA, LLC | 14 | $220 |
| AstraZeneca | 12 | $164 |
| Medtronic(2 entities) | 4 | $151 |
| Amryt Pharma Holdings Ltd | 6 | $106 |
| Corcept Therapeutics | 5 | $98 |
| Amarin Pharma, Inc. | 6 | $97 |
| Amneal Pharmaceuticals LLC | 5 | $82 |
| Boehringer Ingelheim | 4 | $57 |
| Clarus Therapeutics Inc. | 3 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $55 |
| Bayer | 2 | $37 |
| Amgen | 2 | $36 |
| IBSA Pharma Inc. | 2 | $35 |
| Merck | 2 | $35 |
| Pfizer | 2 | $32 |
| Dexcom, Inc. | 2 | $32 |
| Ipsen Biopharmaceuticals, Inc | 1 | $27 |
| Johnson & Johnson | 2 | $25 |
| Abbott | 2 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Antares Pharma, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $16 |
| Sequel Med Tech, LLC | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$104
How this compares
$1,780 in reported general payments places this provider in the 55th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 173 | $280,603 |
| JardianceEmpagliflozin | 180 | $177,028 |
| TrulicityDulaglutide | 100 | $124,098 |
| Tresiba Flextouch U-200Insulin Degludec | 40 | $81,117 |
| FarxigaDapagliflozin Propanediol | 32 | $33,026 |
| Humalog Kwikpen U-100Insulin Lispro | 83 | $29,009 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 50 | $28,819 |
| Tresiba Flextouch U-100Insulin Degludec | 36 | $27,503 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 149 | $27,121 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 27 | $26,508 |
| Repatha SureclickEvolocumab | 29 | $25,133 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $23,034 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $20,680 |
| InvokanaCanagliflozin | 14 | $20,433 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 37 | $17,813 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $325 | $290,523190 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $57 | $212,806207 claims |
| Lilly USA, LLCTrulicity, Humalog, Humulin 70-30 | $220 | $135,083148 claims |
| MerckJanumet Xr, Janumet | $35 | $39,07649 claims |
| AstraZenecaFarxiga | $164 | $33,02632 claims |
| Johnson & JohnsonInvokana | $25 | $20,43314 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $82 | $4,334362 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Canton
- Charles SmithCanton$5.3M
- Arvind KrishnaCanton$3.1M
- Kevin WietechaCanton$127K
- Toby BriskinBedford$9.8M
- Kevin PantaloneCleveland$4M
- Elena ChristofidesColumbus$3.5M
- Bartolome BurgueraCleveland$3.1M
- Steven IngColumbus$1.9M
- Kathleen DunganColumbus$1.4M
- Kyaw SoeColumbus$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.